A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: A third-party us payer perspective

Value in Health

Volumn 12, Issue 5, 2009, Pages 674-686

  St Charles, Meaghan ^a   Lynch, Peter ^b   Graham, Claudia ^b   Minshall, Michael E ^a  

^a IQVIA   (United States)

^b MEDTRONIC INC   (United States)

Author keywords

Continuous subcutaneous insulin injection; Cost effectiveness analysis; Multiple daily injections; Type 1 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BECAPLERMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG INTERMITTENT THERAPY; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; TREATMENT RESPONSE; ULCER;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CHILD; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DRUG COSTS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 67649958298     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00478.x     Document Type: Article

References (38)

1. Juvenile Diabetes Research Foundation-Australia. Diabetes Statistics. Available from: http://www.jdrf.org.au/publications/factsheets/ diabetesstatistics.html [Accessed January 25, 2005].
2. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: metaanalysis of randomised controlled trials. BMJ 2002 324 : 1 6.
3. Weissberg-Benchell J, Antisdel-Lomaglio J, Insulin Seshadri R. Pump therapy: a meta-analysis. Diabetes Care 2003 26 : 1079 87.
4. Cohen N, Minshall M, Sharon-Nash L, et al. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin. Pharmacoeconomics 2007 25 : 881 97.
5. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabet Med 2004 22 : 1239 45.
6. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004 20 (Suppl. 1 S5 26.
7. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004 20 (Suppl. 1 S27 40.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 86.
10. Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004 27 : 1554 8.
11. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002 19 : 746 51.
12. Bruttomesso D, Pianta A, Crazzolara D, et al. Continuous subcutaneous insulin infusion (CSII) in the veneto region: efficacy, acceptability and quality of life. Diabet Med 2002 19 : 628 34.
13. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003 289 : 2254 64.
14. Bode BW, Sabbah HT, Gross TM, et al. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002 18 (Suppl. 1 S14 20.
15. US Department of Labor, Bureau of Labor Statistics. Consumer price index for the healthcare sector. Internet communication. 2003 Available from: http://data.bls.gov/PDQ/servlet/SurveyOutputServlet?data-tool= latest-numbers&series-id=CUUR0000SAM&output-view=pct-1mth [Accessed December 9, 2007].
16. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002 22 : 340 9.
17. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000 38 : 583 637.
18. Carrington AL, Mawdsley SK, Morley M, et al. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996 32 : 19 25. (Pubitemid 26191382)
19. National Institute for Clinical Excellence (NICE). Guidance on the use of long-acting insulin analogues for the treatment of diabetes - insulin glargine. National Institute for Clinical Excellence (NICE) January 12, 2002; Technology Appraisal Guidance - No. 53. Available from: http://www.nice.org.uk/nicemedia/ pdf/53-Insulin-analogues-full-guidance.pdf [Accessed December 9, 2007].
20. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004 27 : 2262 5.
21. Bullano MF, Al-Zakwani IS, Fisher MD, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005 21 : 291 8.
22. O'Brien J, Shompe L, Kavanagh P, et al. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998 21 : 1122 8.
23. Currie C. Multivariate models of health-related utility and the fear of hypoglyaecemia in people with diabetes. Curr Med Res Opin 2006 22 : 1523 34.
24. Halpern EF, Weinstein MC, Hunink MG, Gazelle GS. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000 20 : 314 22.
25. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003 25 : 1017 38.
26. Mark DB, Simons TA. Fundamentals of economic analysis. American Heart Journal 1999 137 (Suppl. 5 S38 40.
27. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003 20 : 586 93.
28. Colquitt JL, Green C, Sidhu MK, Hartwell N. Clinical and Cost-Effectiveness of Continuous Subcutaneous Infusions for Diabetes. Report No. 8. Tunbridge Wells, Kent : Gray Publishing, 2004.
29. Aschner P, Kipnes M, Lunceford J, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 29 : 2632 7.
30. American Diabetes Association (ADA). Diabetes: Heart Disease and Stroke. Available from: http://www.diabetes.org/heart-disease-stroke.jsp [Accessed December 9, 2007].
31. Nicolucci A, Maione I, Franciosi M, et al. Quality of life and treatment satisfaction in adults with type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 2008 25 : 213 20.
32. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 53.
33. Medicode. DRG Guidebook. A Comprehensive Resource to the DRG Classification System (17th ed.). Reston, VA : St. Anthony Publishing, 2001.
34. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003 26 : 2305 10.
35. Thompson. Drug Topics Red Book. Montvale, NJ : Medical Economics Company, 2004.
36. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999 131 : 660 7.
37. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001 27 : 347 51.
38. Hoogma RPLM, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2006 23 : 141 7.